These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 27240810)

  • 1. Cerebrospinal Fluid Amyloid β1-42, Tau, and Alpha-Synuclein Predict the Heterogeneous Progression of Cognitive Dysfunction in Parkinson's Disease.
    Kang JH
    J Mov Disord; 2016 May; 9(2):89-96. PubMed ID: 27240810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study.
    Kang JH; Mollenhauer B; Coffey CS; Toledo JB; Weintraub D; Galasko DR; Irwin DJ; Van Deerlin V; Chen-Plotkin AS; Caspell-Garcia C; Waligórska T; Taylor P; Shah N; Pan S; Zero P; Frasier M; Marek K; Kieburtz K; Jennings D; Tanner CM; Simuni T; Singleton A; Toga AW; Chowdhury S; Trojanowski JQ; Shaw LM;
    Acta Neuropathol; 2016 Jun; 131(6):935-49. PubMed ID: 27021906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal striatal dopamine transporter binding and cerebrospinal fluid alpha-synuclein, amyloid beta, total tau, and phosphorylated tau in Parkinson's disease.
    Nabizadeh F; Pirahesh K; Ramezannezhad E
    Neurol Sci; 2023 Feb; 44(2):573-585. PubMed ID: 36227385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal fluid alpha-synuclein, amyloid beta, total tau, and phosphorylated tau in tremor-dominant Parkinson's disease.
    Nabizadeh F; Sodeifian F; Kargar A
    Acta Neurol Belg; 2023 Aug; 123(4):1429-1437. PubMed ID: 37000407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The associations of cerebrospinal fluid biomarkers with cognition, and rapid eye movement sleep behavior disorder in early Parkinson's disease.
    Tao M; Dou K; Xie Y; Hou B; Xie A
    Front Neurosci; 2022; 16():1049118. PubMed ID: 36507360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amyloid-β and α-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease.
    Stav AL; Aarsland D; Johansen KK; Hessen E; Auning E; Fladby T
    Parkinsonism Relat Disord; 2015 Jul; 21(7):758-64. PubMed ID: 25971633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Association of CSF sTREM2 With Cognitive Decline and Its Dynamic Change in Parkinson's Disease: Analysis of the PPMI Cohort.
    Qin Q; Wan H; Wang D; Li J; Qu Y; Zhao J; Li J; Xue Z
    Front Aging Neurosci; 2022; 14():892493. PubMed ID: 35783125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease.
    Parnetti L; Farotti L; Eusebi P; Chiasserini D; De Carlo C; Giannandrea D; Salvadori N; Lisetti V; Tambasco N; Rossi A; Majbour NK; El-Agnaf O; Calabresi P
    Front Aging Neurosci; 2014; 6():53. PubMed ID: 24744728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal Alterations of Alpha-Synuclein, Amyloid Beta, Total, and Phosphorylated Tau in Cerebrospinal Fluid and Correlations Between Their Changes in Parkinson's Disease.
    Dolatshahi M; Pourmirbabaei S; Kamalian A; Ashraf-Ganjouei A; Yaseri M; Aarabi MH
    Front Neurol; 2018; 9():560. PubMed ID: 30050494
    [No Abstract]   [Full Text] [Related]  

  • 10. Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson's Disease.
    Skogseth RE; Bronnick K; Pereira JB; Mollenhauer B; Weintraub D; Fladby T; Aarsland D
    J Parkinsons Dis; 2015; 5(4):783-92. PubMed ID: 26599300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brain Amyloid Contribution to Cognitive Dysfunction in Early-Stage Parkinson's Disease: The PPMI Dataset.
    Fiorenzato E; Biundo R; Cecchin D; Frigo AC; Kim J; Weis L; Strafella AP; Antonini A
    J Alzheimers Dis; 2018; 66(1):229-237. PubMed ID: 30282359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Longitudinal Study of Total and Phosphorylated α-Synuclein with Other Biomarkers in Cerebrospinal Fluid of Alzheimer's Disease and Mild Cognitive Impairment.
    Wang H; Stewart T; Toledo JB; Ginghina C; Tang L; Atik A; Aro P; Shaw LM; Trojanowski JQ; Galasko DR; Edland S; Jensen PH; Shi M; Zhang J;
    J Alzheimers Dis; 2018; 61(4):1541-1553. PubMed ID: 29376878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders.
    Mollenhauer B; Parnetti L; Rektorova I; Kramberger MG; Pikkarainen M; Schulz-Schaeffer WJ; Aarsland D; Svenningsson P; Farotti L; Verbeek MM; Schlossmacher MG
    J Neurochem; 2016 Oct; 139 Suppl 1():290-317. PubMed ID: 26452984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What is the Clinical Significance of Cerebrospinal Fluid Biomarkers in Parkinson's disease? Is the Significance Diagnostic or Prognostic?
    Kim D; Paik JH; Shin DW; Kim HS; Park CS; Kang JH
    Exp Neurobiol; 2014 Dec; 23(4):352-64. PubMed ID: 25548535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrospinal α-Synuclein Oligomers Reflect Disease Motor Severity in DeNoPa Longitudinal Cohort.
    Majbour NK; Abdi IY; Dakna M; Wicke T; Lang E; Ali Moussa HY; Thomas MA; Trenkwalder C; Safieh-Garabedian B; Tokuda T; Mollenhauer B; El-Agnaf O
    Mov Disord; 2021 Sep; 36(9):2048-2056. PubMed ID: 33978256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tau/α-synuclein ratio and inflammatory proteins in Parkinson's disease: An exploratory study.
    Delgado-Alvarado M; Gago B; Gorostidi A; Jiménez-Urbieta H; Dacosta-Aguayo R; Navalpotro-Gómez I; Ruiz-Martínez J; Bergareche A; Martí-Massó JF; Martínez-Lage P; Izagirre A; Rodríguez-Oroz MC
    Mov Disord; 2017 Jul; 32(7):1066-1073. PubMed ID: 28548309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum Insulin-Like Growth Factor-1 in Parkinson's Disease; Study of Cerebrospinal Fluid Biomarkers and White Matter Microstructure.
    Ghazi Sherbaf F; Mohajer B; Ashraf-Ganjouei A; Mojtahed Zadeh M; Javinani A; Sanjari Moghaddam H; Shirin Shandiz M; Aarabi MH
    Front Endocrinol (Lausanne); 2018; 9():608. PubMed ID: 30450079
    [No Abstract]   [Full Text] [Related]  

  • 18. Machine learning-based prediction of longitudinal cognitive decline in early Parkinson's disease using multimodal features.
    Almgren H; Camacho M; Hanganu A; Kibreab M; Camicioli R; Ismail Z; Forkert ND; Monchi O
    Sci Rep; 2023 Aug; 13(1):13193. PubMed ID: 37580407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Temporal trajectory of biofluid markers in Parkinson's disease.
    Baek MS; Lee MJ; Kim HK; Lyoo CH
    Sci Rep; 2021 Jul; 11(1):14820. PubMed ID: 34285331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal Fluid Biomarkers of Cognitive Decline in Parkinson's Disease.
    Johar I; Mollenhauer B; Aarsland D
    Int Rev Neurobiol; 2017; 132():275-294. PubMed ID: 28554411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.